3105 related articles for article (PubMed ID: 7577083)
1. Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice.
Hofs HP; Wagener DJ; De Vos D; Ottenheijm HC; Winkens HJ; Bovee PH; De Grip WJ
Eur J Cancer; 1995; 31A(9):1526-30. PubMed ID: 7577083
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of cisplatin antitumour activity by Ethyldeshydroxy-Sparsomycin in L1210 leukemia.
Hofs HP; Wagener DJ; De Valk-Bakker V; Van Rennes H; Van Zeist AJ; Van Den Broek LA; Ottenheijm HC
Anticancer Res; 1992; 12(1):167-70. PubMed ID: 1567164
[TBL] [Abstract][Full Text] [Related]
3. The effect of ethyldeshydroxy-sparsomycin and cisplatin on the intracellular glutathione level and glutathione S-transferase activity.
Hofs HP; Wagener TD; de Valk-Bakker V; van Rennes H; Doesburg WH; Ottenheijm HC; de Grip WJ
Anticancer Drugs; 1997 Apr; 8(4):349-57. PubMed ID: 9180388
[TBL] [Abstract][Full Text] [Related]
4. Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.
Hofs HP; Wagener DJ; de Valk-Bakker V; van Rennes H; van Zeist AJ; van den Broek LA; Ottenheijm HC
Cancer Chemother Pharmacol; 1993; 31(4):289-94. PubMed ID: 8422692
[TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent enhancement of antitumor activity of ethyldeshydroxy-sparsomycin in combination with classical antineoplastic agents.
Hofs HP; Wagener DJ; de Valk-Bakker V; van Rennes H; de Vos D; Doesburg WH; Ottenheijm HC; de Grip WJ
Anticancer Drugs; 1995 Apr; 6(2):277-84. PubMed ID: 7795276
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.
Fiebig HH; Berger DP; Köpping K; Ottenheijm HC; Zylicz Z
J Cancer Res Clin Oncol; 1990; 116(6):550-6. PubMed ID: 2254373
[TBL] [Abstract][Full Text] [Related]
7. Concentration and sequence dependent synergism of ethyldeshydroxy-sparsomycin in combination with antitumor agents.
Hofs HP; Wagener DJ; de Valk-Bakker V; van Rennes H; Ottenheijm HC; de Grip WJ
Anticancer Drugs; 1994 Feb; 5(1):35-42. PubMed ID: 8186428
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.
Hofs HP; Wagener DJ; De Valk-Bakker V; Van Rennes H; De Vos D; Doesburg WH; Ottenheijm HC; De Grip WJ
Invest New Drugs; 1995; 13(1):23-32. PubMed ID: 7499104
[TBL] [Abstract][Full Text] [Related]
9. In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.
Zylicz Z; Wagener DJ; van Rennes H; van der Kleijn E; Lelieveld P; van den Broek LA; Ottenheijm HC
Invest New Drugs; 1988 Dec; 6(4):285-92. PubMed ID: 3229941
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of cisplatin antitumor activity on L1210 leukemia s.c. by sparsomycin and three of its analogues.
Zylicz Z; Hofs HP; Wagener DJ
Cancer Lett; 1989 Jul; 46(2):153-7. PubMed ID: 2752385
[TBL] [Abstract][Full Text] [Related]
11. Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development.
Fiebig HH; Schmid JR; Bieser W; Henss H; Lohr GW
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):937-48. PubMed ID: 3665999
[TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent.
Hendriks HR; Plowman J; Berger DP; Paull KD; Fiebig HH; Fodstad O; Dreef-van der Meulen HC; Henrar RE; Pinedo HM; Schwartsmann G
Ann Oncol; 1992 Nov; 3(9):755-63. PubMed ID: 1450065
[TBL] [Abstract][Full Text] [Related]
13. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo.
Gianasi E; Wasil M; Evagorou EG; Keddle A; Wilson G; Duncan R
Eur J Cancer; 1999 Jun; 35(6):994-1002. PubMed ID: 10533484
[TBL] [Abstract][Full Text] [Related]
14. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
[TBL] [Abstract][Full Text] [Related]
15. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
16. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.
Pezzoni G; Grandi M; Biasoli G; Capolongo L; Ballinari D; Giuliani FC; Barbieri B; Pastori A; Pesenti E; Mongelli N
Br J Cancer; 1991 Dec; 64(6):1047-50. PubMed ID: 1764367
[TBL] [Abstract][Full Text] [Related]
17. A new antitumour agent, batracylin, selected by a preclinical solid tumour model.
Atassi G; Dumont P; Kabbe HJ; Yoder O
Drugs Exp Clin Res; 1988; 14(9):571-4. PubMed ID: 3229319
[TBL] [Abstract][Full Text] [Related]
18. Lipophilic analogues of sparsomycin as strong inhibitors of protein synthesis and tumor growth: a structure-activity relationship study.
van den Broek LA; Lázaro E; Zylicz Z; Fennis PJ; Missler FA; Lelieveld P; Garzotto M; Wagener DJ; Ballesta JP; Ottenheijm HC
J Med Chem; 1989 Aug; 32(8):2002-15. PubMed ID: 2754719
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of sparsomycin analogs as potential antitumor agents.
Dubois RJ; Lin CC; Michel BL
J Pharm Sci; 1975 May; 64(5):825-9. PubMed ID: 1151655
[TBL] [Abstract][Full Text] [Related]
20. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
